Published in Diabetes on September 01, 2012
The adipocyte-inducible secreted phospholipases PLA2G5 and PLA2G2E play distinct roles in obesity. Cell Metab (2014) 0.91
Epigenetic regulation of depot-specific gene expression in adipose tissue. PLoS One (2013) 0.89
Obesity promotes colonic stem cell expansion during cancer initiation. Cancer Lett (2015) 0.86
Nuclear corepressors mediate the repression of phospholipase A2 group IIa gene transcription by thyroid hormone. J Biol Chem (2013) 0.82
The PGE2 EP3 Receptor Regulates Diet-Induced Adiposity in Male Mice. Endocrinology (2015) 0.81
Grape seed procyanidin supplementation to rats fed a high-fat diet during pregnancy and lactation increases the body fat content and modulates the inflammatory response and the adipose tissue metabolism of the male offspring in youth. Int J Obes (Lond) (2014) 0.77
PGE2, Kidney Disease, and Cardiovascular Risk: Beyond Hypertension and Diabetes. J Am Soc Nephrol (2015) 0.77
Metabolomic profiling in liver of adiponectin-knockout mice uncovers lysophospholipid metabolism as an important target of adiponectin action. Biochem J (2015) 0.76
Butyrate attenuates lipolysis in adipocytes co-cultured with macrophages through non-prostaglandin E2-mediated and prostaglandin E2-mediated pathways. Lipids Health Dis (2016) 0.75
Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest (2003) 41.22
Inflammation and metabolic disorders. Nature (2006) 33.33
Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest (2003) 32.01
Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science (1993) 25.54
Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest (2007) 20.19
Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature (2007) 11.59
CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med (2009) 11.28
Inflammatory mechanisms in obesity. Annu Rev Immunol (2011) 9.83
Dynamics of fat cell turnover in humans. Nature (2008) 9.80
Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med (2009) 9.71
Mechanisms linking obesity with cardiovascular disease. Nature (2006) 9.07
Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol (2008) 8.43
Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. EMBO J (2007) 7.30
Weight loss and lipolysis promote a dynamic immune response in murine adipose tissue. J Clin Invest (2010) 4.56
Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat Med (2009) 3.97
PGC-1alpha coactivates PDK4 gene expression via the orphan nuclear receptor ERRalpha: a mechanism for transcriptional control of muscle glucose metabolism. Mol Cell Biol (2005) 2.93
Dynamics of human adipose lipid turnover in health and metabolic disease. Nature (2011) 2.90
Fatty acids, obesity, and insulin resistance: time for a reevaluation. Diabetes (2011) 2.43
AdPLA ablation increases lipolysis and prevents obesity induced by high-fat feeding or leptin deficiency. Nat Med (2009) 1.88
Inflammatory lipid mediators in adipocyte function and obesity. Nat Rev Endocrinol (2010) 1.87
International Union of Pharmacology. LXXI. Free fatty acid receptors FFA1, -2, and -3: pharmacology and pathophysiological functions. Pharmacol Rev (2008) 1.80
Adipose tissue lipolysis as a metabolic pathway to define pharmacological strategies against obesity and the metabolic syndrome. Pharmacol Res (2006) 1.80
Reduced expression of the liver/beta-cell glucose transporter isoform in glucose-insensitive pancreatic beta cells of diabetic rats. Proc Natl Acad Sci U S A (1990) 1.71
Identification and functional characterization of adipose-specific phospholipase A2 (AdPLA). J Biol Chem (2008) 1.42
Chronic hyperglycemia, independent of plasma lipid levels, is sufficient for the loss of beta-cell differentiation and secretory function in the db/db mouse model of diabetes. Diabetes (2005) 1.31
Structures of free and inhibited human secretory phospholipase A2 from inflammatory exudate. Science (1991) 1.31
High-carbohydrate, high-fat diet-induced metabolic syndrome and cardiovascular remodeling in rats. J Cardiovasc Pharmacol (2011) 1.31
Secretory, endocrine and autocrine/paracrine function of the adipocyte. J Nutr (2000) 1.18
Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats. Br J Pharmacol (2010) 1.16
Structure of recombinant human rheumatoid arthritic synovial fluid phospholipase A2 at 2.2 A resolution. Nature (1991) 1.13
Genetic ablation of calcium-independent phospholipase A2gamma prevents obesity and insulin resistance during high fat feeding by mitochondrial uncoupling and increased adipocyte fatty acid oxidation. J Biol Chem (2010) 1.08
Linking the inflammasome to obesity-related disease. Nat Med (2011) 1.05
Comparative protection against rat intestinal reperfusion injury by a new inhibitor of sPLA2, COX-1 and COX-2 selective inhibitors, and an LTC4 receptor antagonist. Br J Pharmacol (2003) 1.05
D-Tyrosine as a chiral precusor to potent inhibitors of human nonpancreatic secretory phospholipase A2 (IIa) with antiinflammatory activity. Chembiochem (2003) 0.99
Transcellular prostaglandin production following mast cell activation is mediated by proximal secretory phospholipase A2 and distal prostaglandin synthase 1. J Biol Chem (1996) 0.96
Antifibrotic activity of an inhibitor of group IIA secretory phospholipase A2 in young spontaneously hypertensive rats. J Immunol (2006) 0.95
Lipid redistribution by α-linolenic acid-rich chia seed inhibits stearoyl-CoA desaturase-1 and induces cardiac and hepatic protection in diet-induced obese rats. J Nutr Biochem (2011) 0.93
Prostanoid-induced inhibition of lipolysis in rat isolated adipocytes: probable involvement of EP3 receptors. Prostaglandins (1992) 0.92
Profiling gene expression induced by protease-activated receptor 2 (PAR2) activation in human kidney cells. PLoS One (2010) 0.92
In obesity and weight loss, all roads lead to the mighty macrophage. J Clin Invest (2010) 0.90
Alleviation of high-fat diet-induced fatty liver damage in group IVA phospholipase A2-knockout mice. PLoS One (2009) 0.90
Mice deficient in group VIB phospholipase A2 (iPLA2gamma) exhibit relative resistance to obesity and metabolic abnormalities induced by a Western diet. Am J Physiol Endocrinol Metab (2010) 0.89
A potent and selective inhibitor of group IIa secretory phospholipase A2 protects rats from TNBS-induced colitis. Int Immunopharmacol (2005) 0.88
Group IVA phospholipase A2 is associated with the storage of lipids in adipose tissue and liver. Prostaglandins Other Lipid Mediat (2008) 0.86
Arachidonic acid and PGE2 regulation of hepatic lipogenic gene expression. J Lipid Res (1999) 0.84
Adipose lipid turnover-a new target in metabolic disease. Nat Rev Endocrinol (2011) 0.77
MR1 presents microbial vitamin B metabolites to MAIT cells. Nature (2012) 3.71
Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev (2004) 3.69
The prevalence and impact of overweight and obesity in an Australian obstetric population. Med J Aust (2006) 3.43
The future of peptide-based drugs. Chem Biol Drug Des (2013) 3.41
Histone deacetylases as regulators of inflammation and immunity. Trends Immunol (2011) 2.18
Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS. J Leukoc Biol (2010) 2.07
Antigen-loaded MR1 tetramers define T cell receptor heterogeneity in mucosal-associated invariant T cells. J Exp Med (2013) 2.04
Proteases universally recognize beta strands in their active sites. Chem Rev (2005) 1.90
Inflammatory lipid mediators in adipocyte function and obesity. Nat Rev Endocrinol (2010) 1.87
Structure, function and pathophysiology of protease activated receptors. Pharmacol Ther (2011) 1.81
Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria. Antimicrob Agents Chemother (2006) 1.72
Aging per se does not influence glucose homeostasis: in vivo and in vitro evidence. Diabetes Care (2003) 1.62
Recognition of vitamin B metabolites by mucosal-associated invariant T cells. Nat Commun (2013) 1.61
Identification of sister chromatids by DNA template strand sequences. Nature (2009) 1.53
Caffeine attenuates metabolic syndrome in diet-induced obese rats. Nutrition (2012) 1.53
Rodent models for metabolic syndrome research. J Biomed Biotechnol (2010) 1.53
Beta-strand mimetics. Chem Rev (2004) 1.52
Fat as an endocrine organ: relationship to the metabolic syndrome. Am J Med Sci (2005) 1.48
Metformin and serious adverse effects. Med J Aust (2004) 1.48
Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death. Proc Natl Acad Sci U S A (2007) 1.46
Histone deacetylase inhibitors in inflammatory disease. Curr Top Med Chem (2009) 1.46
Inhibition of CCR6 function reduces the severity of experimental autoimmune encephalomyelitis via effects on the priming phase of the immune response. J Immunol (2009) 1.43
Single turn peptide alpha helices with exceptional stability in water. J Am Chem Soc (2005) 1.42
A small molecule C5a receptor antagonist protects kidneys from ischemia/reperfusion injury in rats. Kidney Int (2003) 1.41
A potent human C5a receptor antagonist protects against disease pathology in a rat model of inflammatory bowel disease. J Immunol (2003) 1.40
Omega-3 fatty acids and metabolic syndrome: effects and emerging mechanisms of action. Prog Lipid Res (2011) 1.39
2: Recent advances in therapy of diabetes. Med J Aust (2003) 1.38
Downsizing human, bacterial, and viral proteins to short water-stable alpha helices that maintain biological potency. Proc Natl Acad Sci U S A (2010) 1.38
Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase. Cell Biochem Biophys (2007) 1.38
Protease inhibitors in the clinic. Med Chem (2005) 1.33
High-carbohydrate, high-fat diet-induced metabolic syndrome and cardiovascular remodeling in rats. J Cardiovasc Pharmacol (2011) 1.31
In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J Hepatol (2003) 1.29
Metabolic syndrome in severe chronic kidney disease: Prevalence, predictors, prognostic significance and effects of risk factor modification. Nephrology (Carlton) (2007) 1.28
The link between abdominal obesity and the metabolic syndrome. Curr Hypertens Rep (2008) 1.28
Determinants of exercise capacity in patients with type 2 diabetes. Diabetes Care (2005) 1.28
Olive leaf extract attenuates cardiac, hepatic, and metabolic changes in high carbohydrate-, high fat-fed rats. J Nutr (2010) 1.23
Screening for heart disease in diabetic subjects. Am Heart J (2005) 1.22
Enzymatic characterization and homology model of a catalytically active recombinant West Nile virus NS3 protease. J Biol Chem (2004) 1.22
Adiponectin multimerization is dependent on conserved lysines in the collagenous domain: evidence for regulation of multimerization by alterations in posttranslational modifications. Mol Endocrinol (2006) 1.20
Cleavage of hemoglobin by hookworm cathepsin D aspartic proteases and its potential contribution to host specificity. FASEB J (2002) 1.20
A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. Drug Discov Today (2007) 1.19
Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats. Br J Pharmacol (2010) 1.16
Update on incretin hormones. Ann N Y Acad Sci (2011) 1.15
Rutin attenuates metabolic changes, nonalcoholic steatohepatitis, and cardiovascular remodeling in high-carbohydrate, high-fat diet-fed rats. J Nutr (2011) 1.14
Age- and stage-dependent accumulation of advanced glycation end products in intracellular deposits in normal and Alzheimer's disease brains. Cereb Cortex (2004) 1.14
Toward drugs for protease-activated receptor 2 (PAR2). J Med Chem (2013) 1.12
Comparative anti-inflammatory activities of antagonists to C3a and C5a receptors in a rat model of intestinal ischaemia/reperfusion injury. Br J Pharmacol (2004) 1.11
An antagonist of human protease activated receptor-2 attenuates PAR2 signaling, macrophage activation, mast cell degranulation, and collagen-induced arthritis in rats. FASEB J (2012) 1.11
Potent cationic inhibitors of West Nile virus NS2B/NS3 protease with serum stability, cell permeability and antiviral activity. J Med Chem (2008) 1.10
Structure of West Nile virus NS3 protease: ligand stabilization of the catalytic conformation. J Mol Biol (2008) 1.10
Quercetin ameliorates cardiovascular, hepatic, and metabolic changes in diet-induced metabolic syndrome in rats. J Nutr (2012) 1.10
Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma. Int J Gynecol Pathol (2005) 1.10
Protective effects of a potent C5a receptor antagonist on experimental acute limb ischemia-reperfusion in rats. J Surg Res (2004) 1.09
Pharmacological inhibition of soluble epoxide hydrolase ameliorates diet-induced metabolic syndrome in rats. Exp Diabetes Res (2011) 1.09
Insights to substrate binding and processing by West Nile Virus NS3 protease through combined modeling, protease mutagenesis, and kinetic studies. J Biol Chem (2006) 1.09
Protective effect of a new C5a receptor antagonist against ischemia-reperfusion injury in the rat small intestine. J Surg Res (2002) 1.08
Characterization of the transcriptional and functional effects of fibroblast growth factor-1 on human preadipocyte differentiation. FASEB J (2006) 1.07
Ellagic acid attenuates high-carbohydrate, high-fat diet-induced metabolic syndrome in rats. Eur J Nutr (2012) 1.07
Site-directed mutagenesis and kinetic studies of the West Nile Virus NS3 protease identify key enzyme-substrate interactions. J Biol Chem (2004) 1.06
Targeting histone deacetylase inhibitors for anti-malarial therapy. Curr Top Med Chem (2009) 1.06
Adiponectin--it's all about the modifications. Int J Biochem Cell Biol (2010) 1.06
The streptozotocin-diabetic rat as a model of the chronic complications of human diabetes. Heart Lung Circ (2003) 1.05
Comparative protection against rat intestinal reperfusion injury by a new inhibitor of sPLA2, COX-1 and COX-2 selective inhibitors, and an LTC4 receptor antagonist. Br J Pharmacol (2003) 1.05
Muscle glycogen inharmoniously regulates glycogen synthase activity, glucose uptake, and proximal insulin signaling. Am J Physiol Endocrinol Metab (2005) 1.04
Ferulic acid improves cardiovascular and kidney structure and function in hypertensive rats. J Cardiovasc Pharmacol (2013) 1.04
Genomic instability of human mammary epithelial cells overexpressing a truncated form of EMSY. J Natl Cancer Inst (2005) 1.03
Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monarticular arthritis in the rat. Arthritis Rheum (2002) 1.03
Exercise prescription for patients with type 2 diabetes and pre-diabetes: a position statement from Exercise and Sport Science Australia. J Sci Med Sport (2011) 1.02
Modular alpha-helical mimetics with antiviral activity against respiratory syncitial virus. J Am Chem Soc (2006) 1.02
Resveratrol--pills to replace a healthy diet? Br J Clin Pharmacol (2011) 1.02
Naringin improves diet-induced cardiovascular dysfunction and obesity in high carbohydrate, high fat diet-fed rats. Nutrients (2013) 1.01
Antagonism of protease-activated receptor 2 protects against experimental colitis. J Pharmacol Exp Ther (2011) 1.01
Protective effect of a human C5a receptor antagonist against hepatic ischaemia-reperfusion injury in rats. J Hepatol (2004) 1.01
Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activity. Mol Pharmacol (2004) 1.00
Resveratrol improves cardiovascular function in DOCA-salt hypertensive rats. Curr Pharm Biotechnol (2011) 1.00
Chronic high-carbohydrate, high-fat feeding in rats induces reversible metabolic, cardiovascular, and liver changes. Am J Physiol Endocrinol Metab (2012) 1.00
Novel agonists and antagonists for human protease activated receptor 2. J Med Chem (2010) 1.00